Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03674242
Title Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 1st Line Treatment of TNBC (TRYbeCA-2)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ERYtech Pharma
Indications

triple-receptor negative breast cancer

Therapies

Carboplatin + Gemcitabine

Carboplatin + Eryaspase + Gemcitabine

Age Groups: senior | adult
Covered Countries ESP | BEL


No variant requirements are available.